The promoter methylation of the Syk gene in nasopharyngeal carcinoma cell lines
- Authors:
- Chong Yan
- Chibo Liu
- Qiaozhi Jin
- Zhihai Li
- Baohong Tao
- Zhiyi Cai
View Affiliations
Affiliations: Department of Otolaryngology - Head and Neck Surgery, Taizhou Municipal Hospital, Taizhou, Zhejiang 318000, P.R. China, Department of Clinical Laboratory, Taizhou Municipal Hospital, Taizhou, Zhejiang 318000, P.R. China
- Published online on: June 19, 2012 https://doi.org/10.3892/ol.2012.763
-
Pages:
505-508
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The aim of this study was to investigate the mRNA and protein expression levels of the Syk gene as well as its promoter methylation in nasopharyngeal carcinoma (NPC) cell lines. The CNE-1 (highly differentiated), CNE-2 (poorly differentiated) and NP69 (non-cancerous human immortalized nasopharyngeal epithelial cells) cell lines were used in the present study. The MS-PCR, Q-RT-PCR and western blotting methods were used to examine the Syk gene promoter methylation levels and mRNA and protein expression in the three cell lines. The promoter methylation levels in CNE-1, CNE-2 and NP69 cells were 36%, 62% and 0, respectively. The mRNA levels in CNE-1 and CNE-2 cells were 42±3.5 and 28±2% of that in NP69, respectively; the protein levels in CNE-1 and CNE-2 cells were 36±4.5 and 16±2.5 of that in NP69, respectively; the statistical differences between groups were significant. The lower differentiation levels of the NPC cell lines correlate with lower levels of mRNA and protein expression of the Syk gene, as well as higher promoter methylation levels.
View References
|
1
|
Tao Q and Chan AT: Nasopharyngeal
carcinoma: molecular pathogenesis and therapeutic developments.
Expert Rev Mol Med. 9:1–24. 2007.PubMed/NCBI
|
|
2
|
Li LL, Shu XS, Wang ZH, Cao Y and Tao Q:
Epigenetic disruption of cell signaling in nasopharyngeal
carcinoma. Chin J Cancer. 30:231–239. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lo KW and Huang DP: Genetic and epigenetic
changes in nasopharyngeal carcinoma. Semin Cancer Biol. 12:451–462.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Niller HH, Wolf H and Minarovits J:
Epigenetic dysregulation of the host cell genome in Epstein-Barr
virus-associated neoplasia. Semin Cancer Biol. 19:158–164. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Buchholz TA and Wazer DE: Molecular
biology and genetics of breast cancer development: a clinical
perspective. Semin Radiat Oncol. 12:285–295. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Taniguchi T, Kobayashi T, Kondo J, et al:
Molecular cloning of a porcine gene syk that encodes a 72-kDa
protein-tyrosine kinase showing high susceptibility to proteolysis.
J Biol Chem. 266:15790–15796. 1991.PubMed/NCBI
|
|
7
|
Medves S and Demoulin JB: Tyrosine kinase
gene fusions in cancer: translating mechanisms into targeted
therapies. J Cell Mol Med. 16:237–248. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stewart ZA and Pietenpol JA: Syk: a new
player in the field of breast cancer. Breast Cancer Res. 3:5–7.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Efremov DG and Laurenti L: The Syk kinase
as a therapeutic target in leukemia and lymphoma. Expert Opin
Investig Drugs. 20:623–636. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Page TH, Smolinska M, Gillespie J,
Urbaniak AM and Foxwell BM: Tyrosine kinases and inflammatory
signalling. Curr Mol Med. 9:69–85. 2009. View Article : Google Scholar
|
|
11
|
Simons MJ: Nasopharyngeal carcinoma as a
paradigm of cancer genetics. Chin J Cancer. 30:79–84. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hutajulu SH, Indrasari SR, Indrawati LP,
et al: Epigenetic markers for early detection of nasopharyngeal
carcinoma in a high risk population. Mol Cancer. 10:482011.
View Article : Google Scholar : PubMed/NCBI
|
